The U.S. Food and Drug Administration has issued an early alert involving certain Medtronic plc and Given Imaging, Inc. Bravo CF capsule delivery devices after Medtronic told customers to quarantine and return affected products because the reflux-monitoring capsule may fail to attach to the esophagus or detach correctly from the delivery catheter. As of August 10, 2026, Medtronic had reported 184 serious injuries associated with the issue and no deaths.
The FDA describes early alerts as notices involving potentially high-risk device problems while the agency continues reviewing whether a manufacturer’s action meets the formal regulatory definition and classification of a recall. In this case, the identified hazards include aspiration or inhalation of the capsule, esophageal perforation, airway obstruction, hemorrhage, laceration, delayed diagnosis and retention of foreign material.
Which Medtronic Bravo devices are affected by the FDA alert?
The affected products are Bravo CF capsule delivery devices sold in five-unit and single-unit configurations under product numbers FGS-0635 and FGS-0636. The FDA says affected lots have expiration dates up to and including October 20, 2027.
Healthcare facilities have been instructed not to use affected devices and to identify and quarantine any unused inventory before returning it to Medtronic for replacement. Lots with an expiration date of December 10, 2027 or later are outside the current scope and do not need to be returned.
Medtronic originally sent the updated customer communication on August 6, while the FDA publicized the issue through its August 27 early alert.
The situation is therefore primarily relevant to hospitals, gastroenterology practices and diagnostic facilities rather than patients storing devices at home.
What is the Bravo reflux testing system used for?
The Bravo system is used to measure acid exposure inside the esophagus when physicians are evaluating gastroesophageal reflux disease and related symptoms.
A small wireless pH capsule is temporarily attached to the lining of the esophagus. The capsule measures acidity over an extended period and transmits information that clinicians can use to determine how frequently gastric acid is entering the esophagus and whether those episodes correspond with symptoms.
The approach allows patients to undergo longer-duration reflux monitoring without the conventional transnasal catheter remaining in place throughout the entire recording period.
The capsule is normally deployed through a single-use delivery device and eventually detaches naturally from the esophageal wall.
The current problem involves the delivery mechanism rather than the diagnostic concept itself.
What can go wrong when the capsule fails to deploy correctly?
Medtronic says affected Bravo CF capsules may fail to attach properly to the patient’s esophagus or fail to separate from the delivery system as intended. The issue involves a component that controls capsule deployment and can be worsened if the delivery device is not maintained in a straight position according to instructions.
If a capsule does not attach to the esophageal mucosa and is pulled back with the catheter, it can potentially move toward the upper airway and be aspirated. Medtronic’s product safety information already recognizes aspiration as a possible complication when the capsule is inadvertently withdrawn after failing to attach.
Other possible outcomes are more invasive. Manipulation or deployment failure can contribute to tears or perforation of esophageal tissue, bleeding or retention of the capsule or delivery component.
These are uncommon procedures compared with high-volume consumer diagnostics, but the consequences of a deployment failure can be serious enough to require additional intervention.
Why does the FDA report 184 serious injuries?
The figure represents serious-injury reports associated with the problem as of August 10 rather than 184 deaths or 184 identical complications.
Medical-device adverse-event reporting captures events that may involve hospitalization, significant intervention, life-threatening complications or other serious outcomes. Such reports are important safety signals but do not by themselves prove that every injury was directly caused by the same manufacturing defect.
The FDA and manufacturer review event reports, device records and manufacturing information to determine patterns and root causes.
In the Bravo case, however, the number is substantial enough that Medtronic has told customers not to use affected devices and the FDA has chosen to issue a public early alert.
The agency reported no deaths associated with the issue as of its latest update.
Has Medtronic had problems with Bravo devices before?
Yes. The FDA says a subset of devices included in the latest action had previously been subject to a June 2025 recall notification.
The observed failure mode is similar, involving capsule deployment, although Medtronic determined that the underlying cause of the latest problem differs from the earlier issue.
Repeated problems involving the same general procedural step can draw particular attention because manufacturers must distinguish whether a recurrence reflects one unresolved design vulnerability, multiple manufacturing failures or user-interface factors that make errors more likely.
The latest communication indicates that both component behavior and maintaining the delivery system in the required straight configuration can influence deployment.
That makes human-factors analysis as relevant as conventional manufacturing investigation.
What should patients who previously had a Bravo test do?
The FDA has not instructed every patient who previously underwent Bravo reflux testing to seek emergency medical care.
The removal action concerns unused affected delivery devices. Patients who have already completed their test without complications are not being told that a normally detached capsule must be retrieved.
Patients experiencing persistent chest pain, difficulty swallowing, breathing problems, bleeding or other concerning symptoms following a recent procedure should contact their healthcare professional promptly, particularly if they were already advised of a procedural complication.
Clinical decisions should be based on individual symptoms and procedural history rather than fear generated solely by a product alert.
That distinction matters because safety stories with large injury numbers can easily be misinterpreted as meaning every person exposed to a product is in danger.
Could the alert affect Medtronic commercially?
The affected product is only one part of Medtronic’s enormous medical-device portfolio, so the direct financial impact may be limited relative to the company’s total sales.
Nevertheless, safety events can create indirect costs through product replacement, investigation, remediation, regulatory oversight and customer confidence.
Medtronic shares closed August 27 at $89.97, down 2.23% for the session, although there is no basis to attribute that market move solely to the Bravo alert because numerous company and broader-market factors can influence daily trading.
For Medtronic, the more important near-term issue is likely operational: identifying all affected lots, replacing hospital inventory and demonstrating that the deployment problem has been adequately controlled.
Why could this story attract unusually high reader interest?
Device safety alerts often generate strong search traffic because they answer an urgent user question: “Was a product used on me?”
The Bravo story combines a globally recognizable manufacturer, an FDA safety warning, a familiar condition such as acid reflux and a large reported injury number. Those elements create legitimate public interest without requiring sensationalization.
For healthcare professionals, the issue is equally practical because affected inventory must be identified and quarantined.
The FDA says it will update its alert if significant new information becomes available, meaning the final regulatory classification and scope could still evolve.
The key fact for now is straightforward: affected Bravo CF delivery devices should not be used, 184 serious injuries had been reported as of August 10, and Medtronic is replacing the affected inventory.
